Cannabis and Mental Health: Why ‘Cannabis’ and ‘d9-THC’ Are Not the Same
Cannabis mental health risk factors depend heavily on cannabinoid exposure, especially THC and CBD ratios. Understanding these factors is essential for assessing psychiatric outcomes. This article clarifies why cannabis and d9-THC are not interchangeable…
Cannabis and Mental Health: It’s Not Just About ‘Cannabis’
Cannabis mental health risk limited benefits are increasingly recognized as dependent on cannabinoid type, dose, and individual factors. This 2025 review highlights the distinct roles of THC and CBD in psychiatric outcomes. Understanding these nuances is…
Medical Cannabis Evidence Map: Broad Promise, Variable Proof
The 2024 medical cannabis evidence map synthesizes 194 systematic reviews across 71 health outcomes, focusing on high-quality evidence. It highlights positive or potentially positive effects for pain, seizures, anxiety, and more. This map guides…
Unveiling Neurological Benefits: Hemp Extracts in Neurological Disorders
Neurological disorders such as epilepsy, Alzheimer's disease, Parkinson's disease, and multiple sclerosis present significant global health care challenges. This review highlights hemp extract neurological disorders benefits, focusing on hemp leaf,…
Vaporized Cannabis vs Placebo for Acute Migraine: A Randomized Trial
This randomized trial evaluates vaporized cannabis acute migraine treatment. The THC+CBD combination showed significant pain relief compared to placebo. These findings support cannabis as a potential option for acute migraine care.
Cannabinoids in Pediatric Care: Clinical Evidence Review
This review focuses on cannabinoid safety pediatric use, summarizing evidence from 276 studies including interventional and observational research. The clinical evidence supports cautious use of cannabinoids in pediatric medicine for select conditions.…
`Cannabinoid Clinical Trials: CBD and WADA Drug Testing`
Clinical Takeaway Daily use of a broad-spectrum CBD supplement containing trace amounts of other cannabinoids can result in urine concentrations of WADA-prohibited substances such as CBG and CBDV, potentially placing athletes at risk for a positive…
AEF0117 THC Interaction Trial Withdrawn: Implications for Selective CB1 Modulation
The withdrawal of the AEF0117 trial delays progress in selective CB1 receptor modulation for managing THC-related effects. This setback impacts potential pharmacological treatments for cannabis use disorder. Clinicians and patients face longer timelines…
Understanding the CBD Entourage Effect and Its Benefits
The CBD entourage effect benefits explain why full spectrum CBD products may provide superior therapeutic outcomes. This effect arises from the synergy between cannabinoids, terpenes, and flavonoids. Understanding these benefits helps users choose more…
United States DEA Cannabis-Related Documents Overview
Cannabis-related regulatory documents published by the DEA provide essential guidance on federal scheduling and enforcement. These documents clarify the classification of marijuana and hemp-derived cannabinoids under the Controlled Substances Act.…